[1]BRUNT E M, WONG V W, NOBILI V, et al. Nonalcoholic fatty liver disease[J]. Nat Rev Dis Primers, 2015, 1:15080.
[2]ARAB J P, ARRESE M, TRAUNER M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease[J]. Annu Rev Pathol, 2018, 13:321-350.
[3]FRIEDMAN S L, NEUSCHWANDER_TETRI B A, RINELLA M, et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med, 2018, 24:908-922.
[4]YE P, XIANG M, LIAO H, et al. Dual-specificity phosphatase 9 protects against non-alcoholic fatty liver disease in mice via ASK1 suppression[J]. Hepatology, 2019,69(11):76-93.
[5]WILLEBRORDS J, PEREIRA I V, MAES M, et al. Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research[J]. Prog Lipid Res, 2015, 59:106-125.
[6]NATIONAL WORKSHOP ON FATTY LIVER AND ALCOHOLIC LIVER DISEASE, FATTY LIVER EXPERT COMMITTEE. Guideline of prevention and treatment for nonalcoholic fatty liver disease:a 2018 update[J]. J Mod Med Health, 2018, 34(5):641-649.
[7]ANSTEE Q M, GOLDIN R D. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research[J]. Int J Exp Pathol, 2006, 87(1):1-16.
[8]ZHOU Y, DING Y L, ZHANG J L, et al. Alpinetin improved high fat diet-induced non-alcoholic fatty liver disease (NAFLD) through improving oxidative stress, inflammatory response and lipid metabolism[J]. Biomed Pharmacother, 2018, 97:1397-1408.
[9]FABBRINI E, SULLIVAN S, KLEIN S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic and clinical implications[J]. Hepatology, 2010, 51(3):679-689.
[10]SEKIYA M, YAHAGI N, MATSUZAKA T, et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression[J]. Hepatology, 2003, 38(6):1529-1539.
[11]TØIBØI K S, KRISTIANSEN M N, HANSEN H H, et al. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis[J]. World J Gastroenterol, 2018, 24(2):179-194.
[12]SINGH D P, KHARE P, ZHU J, et al. A novel cobiotic-based preventive approach against high-fat diet-induced adiposity, nonalcoholic fatty liver and gut derangement in mice[J]. Int J Obes (Lond), 2016, 40(3):487-496.
[13]LIEBER C S, LEO M A, MAK K M, et al. Model of nonalcoholic steatohepatitis[J]. Am J Clin Nutr, 2004, 79(3):502-509.
[14]LAU J K, ZHANG X, YU J. Animal models of non-alcoholic fatty liver disease:current perspectives and recent advances[J]. J Pathol, 2017, 241(1):36-44.
[15]TRAK-SMAYRA V, PARADIS V, MASSART J, et al. Pathology of the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie diet[J]. Int J Exp Pathol, 2011, 92(6):413-421.
[16]FELLMANN L, NASCIMENTO A R, TIBIRICA E, et al. Murine models for pharmacological studies of the metabolic syndrome[J]. Pharmacol Ther, 2013, 137(3):331-340.
[17]XIONG L, CHEN L, ZHANG L L. Mechanism of high glucose-induced hepatic steatosis[J].China Health Care Nutr(中国保健营养), 2013, 9:22-24.
[18]YAN S Y. The biochemical mechanism studied on tetracycline-induced nonalcoholic fatty liver disease[D]. Changsha:Hunan Normal University, 2014.
[19]ZHANG Z B. Effects and mechanisms of improvement of emodin on Simple hepatic steatosis of non-alcoholic fatty liver[D]. Nanjing:Nanjing University of Chinese Medicine, 2012.
[20]SANTHEKADUR P K, KUMAR D P, SANYAL A J. Preclinical models of non-alcoholic fatty liver disease[J]. J Hepatol, 2018, 68(2):230-237.
[21]HEIER E C, MEIER A, JULICH-HAERTEL H, et al. Murine CD103(+) dendritic cells protect against steatosis progression towards steatohepatitis[J]. J Hepatol, 2017, 66(6):1241-1250.
[22]GIUSTO M, BARBERI L, DI S F, et al. Skeletal muscle myopenia in mice model of bile duct ligation and carbon tetrachloride-induced liver cirrhosis[J]. Physiol Rep, 2017, 5(7):e13153.
[23]LIU Y, SONG H, WANG L, et al. Hepatoprotective and antioxidant activities of extracts from Salvia-Nelumbinis naturalis against nonalcoholic steatohepatitis induced by methionine- and choline-deficient diet in mice[J]. J Transl Med, 2014, 12:315.
[24]CORBIN K D, ZEISEL S H. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression[J]. Curr Opin Gastroenterol, 2012, 28(2):159-165.
[25]SAVARD C, TARTAGLIONE E V, KUVER R, et al. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis[J]. Hepatology, 2013, 57(1):81-92.
[26]CHEN Y Z, CHEN C L, TIAN X, et al. Research advances in animal models based on the pathogenesis and treatment of nonalcoholic fatty liver disease[J]. J Clin Hepatol(临床肝胆病杂志), 2017, 33(12):2457-2461.
[27]HANAFI M Y, ZAHER E L M, EL-ADELY S E M, et al. The therapeutic effects of bee venom on some metabolic and antioxidant parameters associated with HFD-induced non-alcoholic fatty liver in rats[J]. Exp Ther Med, 2018, 15(6):5091-5099.
[28]HANDA P, MORGAN-STEVENSON V,MALIKEN B D, et al. Iron overload results in hepatic oxidative stress, immune cell activation, and hepatocellular ballooning injury, leading to nonalcoholic steatohepatitis in genetically obese mice[J]. Am J Physiol Gastrointest Liver Physiol, 2016, 310(2):117-127.
[29]RINELLA M E, ELIAS M S, SMOLAK R R, et al. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet[J]. J Lipid Res, 2008, 49(5):1068-1076.
[30]LEGRY V, VAN R D M, LAMBERT B, et al. Endoplasmic reticulum stress does not contribute to steatohepatitis in obese and insulin-resistant high-fat-diet-fed foz/foz mice[J]. Clin Sci (Lond), 2014, 127(7):507-518.
[31]WANG Y L, LI J, LIU L J, et al. A cell model of nonalcoholic steatohepatitis induced by FFA:establishment and dynamic monitoring[J]. Chin J Integr Tradit West Med Liver Dis(中西医结合肝病杂志), 2013, 23(4):225-227.
[32]DAI N, ZHOU P, ZHANG Y Y, et al. Effect of aloe-elodin on non-alcoholic steatohepatitis cells model[J]. J Jiangsu Univ (Med Ed)(江苏大学学报:医学版), 2014, 24(6):478-482.
[33]BARNETT R. Liver cirrhosis [J]. Lancet, 2018, 392(10144):275.
[34]JIANG T, WANG L, LI X, et al. Inositol-requiring enzyme 1-mediated endoplasmic reticulum stress triggers apoptosis and fibrosis formation in liver cirrhosis rat models[J]. Mol Med Rep, 2015, 11(4):2941-2946.
[35]CAI Y, LU D, ZOU Y, et al. Curcumin protects against intestinal origin endotoxemia in rat liver cirrhosis by targeting PCSK9[J]. J Food Sci, 2017, 82(3):772-780.
[36]AREZZINI B, LUNGHI B, LUNGARELLA G, et al. Iron overload enhances the development of experimental liver cirrhosis in mice[J]. Int J Biochem Cell Biol, 2003, 35(4):486-495.
[37]ABDUL-HAMID M, AHMED R R, MOUSTAFA N, et al. The antifibrogenic effect of etanercept on development of liver cirrhosis induced by thioacetamide in rats[J]. Ultrastruct Pathol, 2017, 41(1):23-35.
[38]ATARASHI M, IZAWA T, MORI M, et al. Dietary iron overload abrogates chemically-induced liver cirrhosis in rats[J]. Nutrients, 2018, 10(10):E1400.
[39]VERBEKE L, MANNAERTS I, SCHIERWAGEN R, et al. FXR Agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis[J]. Sci Rep, 2016, 6:33453.
[40]HARDY T, OAKLEY F, ANSTEE Q M, et al. Nonalcoholic fatty liver disease: pathogenesis and disease spectrum[J]. Annu Rev Pathol, 2016, 11:451-496.
[41]MARENGO A, ROSSO C, BUGIANESI E. Liver cancer: connections with obesity, fatty liver, and cirrhosis[J]. Annu Rev Med, 2016, 67:103-117.
[42]WOLF M J, ADILI A, PIOTROWITZ K, et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes[J]. Cancer Cell, 2014, 26(4):549-564.
[43]REIBERGER T, CHEN Y, RAMJIAWAN R R, et al. An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis[J]. Nat Protoc, 2015, 10(8):1264-1274.
[44]ALVAREZ-GARCIA V, TAWIL Y, WISE H M, et al. Mechanisms of PTEN loss in cancer: it′s all about diversity[J]. Semin Cancer Biol, 2019.
[45]WATANABE S, HORIE Y, KATAOKA E, et al. Non-alcoholic steatohepatitis and hepatocellular carcinoma:lessons from hepatocyte-specific phosphatase and tensin homolog (PTEN)-deficient mice[J]. J Gastroenterol Hepatol, 2007, 22(suppl 1):96-100.
[46]TSUCHIDA T, LEE Y A, FUJIWARA N, et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer[J]. J Hepatol, 2018, 69(2):385-395.
[47]ASGHARPOUR A, CAZANAVE S C, PACANA T, et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer[J]. J Hepatol, 2016, 65(3):579-588.
[48]KOHJIMA M, HIGUCHI N, KATO M, et al. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease[J]. Int J Mol Med, 2008, 21(4):507-511.
[49]BATATINHA H A, LIMA E A, TEIXEIRA A A, et al. Association between aerobic exercise and rosiglitazone avoided the NAFLD and liver inflammation exacerbated in PPAR-alpha knockout mice[J]. J Cell Physiol, 2017, 232(5):1008-1019.
[50]CANO A, BUQUE X, MARTINEZ-UNA M, et al. Methionine adenosyltransferase 1A gene deletion disrupts hepatic very low-density lipoprotein assembly in mice[J]. Hepatology, 2011, 54(6):1975-1986.
[51]BYRNE C D, TARGHER G. NAFLD:a multisystem disease[J]. J Hepatol, 2015, 62(1):S47-S64.
[52]COLE B K, FEAVER R E, WAMHOFF B R, et al. Non-alcoholic fatty liver disease(NAFLD) models in drug discovery[J]. Expert Opin Drug Discov, 2018, 13(2):193-205.
[53]ROTMAN Y, SANYAL A J. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease[J]. Gut, 2017, 66(1):180-190.
[54]QIANG X, XU L, ZHANG M, et al. Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress[J]. Biochem Biophys Res Commun, 2016, 472(4):603-609.